ArticleCancer research2018
Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
Abstract read
In one paragraph
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed.
- Imaging xCT with Immuno-PET in Therapy-Resistant Non-Small Cell Lung Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma.bioRxiv : the preprint server for biology · 2026Article
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- A novel therapeutic monoclonal antibody targeting PZR demonstrates potent anti-metastatic efficacy in triple-negative breast cancer.Journal of translational medicine · 2026Article
- Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Looking backward to move forward: a chemist's perspective on the future of radiopharmaceuticals.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026Article
- Fc-Engineering Improves PET Imaging of Anti-Mesothelin VH-Fc across Multiple Tumor Mouse Models and Reveals Sex-Specific Renal Clearance.Bioconjugate chemistry · 2026Article
- Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment.Nature reviews. Cancer · 2025Review
- MIB guides: [Molecular imaging and biology · 2025Article
- Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody.Journal of cancer research and clinical oncology · 2025Article
- Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled withEJNMMI radiopharmacy and chemistry · 2025Article
- IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Advances in Tracing Techniques: Mapping the Trajectory of Mesenchymal Stem-Cell-Derived Extracellular Vesicles.Chemical & biomedical imaging · 2025Review
- Measurement of specific and nonspecific tissue uptake of antibodies in tumor by SPECT imaging and nonlinear compartmental modeling.EJNMMI research · 2025Article
- PET Imaging Expedites Detection of Aberration in the Humanization of an Annexin A1 Targeting Antibody.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Clinical Scaleup of Humanized AnnA1 Antibody Yielded Unexpected High Reticuloendothelial (RES) Uptake in Mice.Antibodies (Basel, Switzerland) · 2025Article
- Preclinical Comparison of [Molecular pharmaceutics · 2025Article
- The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models.Therapeutic advances in medical oncology · 2025Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Sai Kiran SharmaDepartments of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrew ChowDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Sebastien MonetteLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University, New York.
Delphine VivierDepartment of Chemistry, Hunter College and the Ph.D. Program in Chemistry, the Graduate Center of the City University of New York, New York, New York.
Jacob PouratDepartments of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Kimberly J EdwardsDepartments of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Thomas R DillingDepartments of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Dalya Abdel-AttiDepartments of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Brian M ZeglisDepartments of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
John T PoirierDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. lewisj2@mskcc.org poirierj@mskcc.org.
Jason S LewisDepartments of Radiology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York. lewisj2@mskcc.org poirierj@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MInvestigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7MCLINICAL SCHOLARS BIOMEDICAL RESEARCH TRAINING PROGRAMT32CA009512 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Ping Chi · 1985 to 2026
$6.3MSummer research experiences for medical students supervised by faculty mentorsR25CA020449 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Charlotte Eielson Ariyan · 1985 to 2026
$6.2MImmuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zrrovalpituzumab, a DLL3-targeting monoclonal antibodyR01CA213448 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI POIRIER, JOHN THOMAS, RUDIN, CHARLES M. · 2017 to 2021
$3.1MPreclinical development of a DLL3-targeted theranostic for small cell lung cancerU01CA213359 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI POIRIER, JOHN THOMAS · 2017 to 2021
$1.7MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA213448NCI NIH HHS R25 CA020449NCI NIH HHS T32 CA009207NCI NIH HHS T32 CA009512NCI NIH HHS U01 CA213359
Abstract
A critical benchmark in the development of antibody-based therapeutics is demonstration of efficacy in preclinical mouse models of human disease, many of which rely on immunodeficient mice. However, relatively little is known about how the biology of various immunodeficient strains impacts the
Indexed as
AnimalsAntineoplastic Agents, ImmunologicalCell Line, TumorCetuximabDisease Models, AnimalFemaleHumansLung NeoplasmsMaleMiceMice, Inbred NODMice, NudeMice, SCIDNeoplasm TransplantationOvarian NeoplasmsPositron-Emission TomographyAntineoplastic Agents, ImmunologicalCetuximabReceptors, FcReceptors, IgGTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.